Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GenSci180
- Development stage
- Preclinical
- Lead developer
- Changchun GeneScience Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Parenteral
01
Overview
GenSci180 (formerly GS24-B025) is a novel bispecific antibody-drug conjugate (BsADC) developed by Changchun GeneScience Pharmaceutical. It is designed to target both cadherin-17 (CDH17) and carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5, or CEA), which are highly expressed tumor-associated antigens in colorectal cancer. GenSci180 is constructed using the company's proprietary HydroLock ADC platform, featuring a highly stable, hydrophilic, cleavable linker conjugated to a potent DNA topoisomerase I (Topo1) inhibitor payload. By simultaneously targeting CDH17 and CEACAM5, GenSci180 achieves enhanced tumor binding and internalization efficiency, leading to superior antitumor efficacy compared to single-target ADCs in preclinical models. The drug is currently in IND-enabling development for the treatment of advanced colorectal cancer.
02
Targets
CDH17 (Cadherin-17)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on GenSci180.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenSci180.